Marksans Pharma’s UK subsidiary, Relonchem Limited, has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for its anti-allergy medicine, the company said in an exchange filing on Thursday.
The approval covers Cetirizine Dihydrochloride 1 mg/ml oral solution, expanding the firm’s allergy treatment portfolio. The oral solution is used to relieve a range of seasonal and year-round allergies, including hay fever and hives.
Shares of Marksans Pharma closed ₹3.87 higher at ₹193.02, up 2.05% following the announcement.
This marks the latest addition to a series of regulatory wins for the company. On Wednesday, its US subsidiary received final approval from the US FDA for Loperamide Hydrochloride Tablets USP, 2 mg, an over-the-counter anti-diarrhoeal medicine.
Earlier this week, Relonchem also secured MHRA approval to market Mefenamic Acid film-coated tablets in 250 mg and 500 mg strengths.
Marksans’ UK and Europe businesses generated ₹245.3 crore in Q2 FY26, with the company meeting revenue and margin targets despite pricing pressures.
For the September quarter, Marksans reported a net profit of ₹98.2 crore, up 1.5% year-on-year, while revenue rose 12% to ₹720 crore. EBITDA declined 1.7% to ₹144.7 crore, with margins narrowing to 20% from 23%.
With two fresh MHRA authorisations this week and a US FDA approval, Marksans’ growth outlook in the UK market remains supportive.
First Published: Nov 20, 2025 4:27 PM IS
